Suggestions
Ivan Strugatsky
Portfolio Manager at STRAN Capital
Ivan Strugatsky is a seasoned professional currently serving as a Director at Hybrid Biotherapeutics Inc.12 With a diverse background in finance and biotechnology, Strugatsky brings a wealth of experience to his role.
Professional Background
Ivan Strugatsky has over 17 years of experience in advisory and investment roles across various asset classes.4 His career has been marked by a combination of skills in:
- Credit analysis and management
- Origination and client relations
- Portfolio management
Current Role
At Hybrid Biotherapeutics Inc., Strugatsky is involved in presenting the company's technology at industry events, such as the Cell and Gene Therapy Summit.2 This suggests he plays a key role in the company's business development and technological advancement efforts.
Previous Experience
Before joining Hybrid Biotherapeutics, Ivan Strugatsky held positions at:
- Stran Capital LLC, where he worked as a Portfolio Manager4
- IVS Advisory, likely in a senior advisory capacity3
Expertise
Strugatsky's expertise spans several areas:
- Advisory services
- Corporate coverage
- Credit analysis
- Technology startups
His knowledge of the tech-startup world is particularly noteworthy, as he has shared insights with professionals, entrepreneurs, and investors in this space.5
Contact Information
For those looking to connect professionally with Ivan Strugatsky, his LinkedIn profile can be found under the username "ivanstrugatsky".1
Ivan Strugatsky's multifaceted experience in finance, investment, and biotechnology positions him as a valuable asset in his role at Hybrid Biotherapeutics Inc., where he likely contributes to both the financial and technological aspects of the company's operations.
Highlights
Interesting interpretation by the court of the bankruptcy code regarding the survivability of residual royalties on asset sales in bankruptcies. "Sellers should [...] protect themselves by either (a) taking a security interest in the assets sold to secure royalty payments, (b) structure the transaction as a license rather than a purchase, or (c) form a joint venture to retain part ownership of the assets."
Congratulations to Ashleigh, Francisco and the whole Provention Bio team!
